c-myc but not Hif-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA

Song,Guanhua; Li,Yanmei; Zhang,Zhiyong; Ren,Xia; Li,Hongjiang; Zhang,Wen; Wei,Ruoying; Pan,Sufei; Shi,Lulu; Bi,Kehong; Jiang,Guosheng

doi:10.3892/or.2013.2395

c-myc but not Hif-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA

Authors:
- Guanhua Song
- Yanmei Li
- Zhiyong Zhang
- Xia Ren
- Hongjiang Li
- Wen Zhang
- Ruoying Wei
- Sufei Pan
- Lulu Shi
- Kehong Bi
- Guosheng Jiang
View Affiliations

Affiliations: Department of Hemato-Oncology, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Key Laboratory for Modern Medicine and Technology of Shandong Province, Key Laboratory for Rare and Uncommon Diseases, Key Medical Laboratory for Tumor Immunology and Traditional Chinese Medicine Immunology of Shandong, Jinan, Shandong 250062, P.R. China, Qianfoshan Hospital of Shandong, Jinan, Shandong 250014, P.R. China
Published online on: April 9, 2013 https://doi.org/10.3892/or.2013.2395
Pages: 2378-2384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in solid tumor growth, progression and metastasis as well as in the proliferation and differentiation of hematological malignancies. However, the molecular mechanism that modulates VEGF expression and secretion in leukemia cells has not yet to be elucidated. The purpose of the present study was to investigate the role of the signal pathway in modulating the expression of VEGF in HL-60 cells. Specific siRNAs targeting VEGF were transfected into HL-60 cells and the VEGF expression was measured with reverse transcription-polymerase chain reaction (RT-PCR) and western blot assay. The cell proliferation of HL-60 cells was detected by the cell counting kit-8 (CCK-8) assay and the differentiation of HL-60 cells induced by all-trans-retinoic acid (ATRA) was detected by the RT-PCR assay and flow cytometry assay for CD11b. The upstream transcription factors that were related to VEGF expression such as P53, SP-1, c-jun, VHL, cox-2, c-myc and stat3 were detected by RT-PCR assay. In addition, the chromatin immunoprecipitation (ChIP) assay was used to reveal the role of c-myc by binding the target gene VEGF. The results demonstrated the hypoxia-inducible factor 1α-related signaling pathway, not the same as in solid tumors, might not play a key role in modulating VEGF expression. c-myc contributes to the modulation of VEGF expression by targeting the promoter of VEGF, which was indicated by the ChIP assay. In conclusion, our data demonstrate that VEGF plays an important role in the differentiation and proliferation of HL-60 cells; c-myc-dependent downregulation of VEGF induced by ATRA contributes to the differentiation of HL-60 cells.

View Figures

View References

1	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
2	Podar K and Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 105:1383–1395. 2005. View Article : Google Scholar : PubMed/NCBI
3	Mayerhofer M, Valent P, Sperr WR, Griffin JD and Sillaber C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 100:3767–3775. 2002. View Article : Google Scholar
4	Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 150:815–821. 1997.PubMed/NCBI
5	Ghosh AK, Shanafelt TD, Cimmino A, et al: Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 113:5568–5574. 2009. View Article : Google Scholar : PubMed/NCBI
6	Jiang GS, Yang WH, Wen PE, Ren X, Tang TH and Ren HQ: HIF-1α independent down-regulation of VEGF expression in HL60 cells after in vitro exposure to ATRA. Blood. 110:42902007.
7	Lidgren A, Hedberg Y, Grankvist K, Torgny R, Vasko J and Ljungberg B: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 11:1129–1135. 2005.PubMed/NCBI
8	Schuch G, Machluf M, Bartsch G Jr, et al: In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 100:4622–4628. 2002. View Article : Google Scholar : PubMed/NCBI
9	Ter Elst A, Ma B, Scherpen FJ, et al: Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res. 71:2761–2771. 2011.PubMed/NCBI
10	Weidenaar AC, ter Elst A, Koopmans-Klein G, et al: High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol. 34:289–296. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bajpai J, Sharma A, Kumar L, et al: Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian J Cancer. 48:316–322. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tee MK, Vigne JL and Taylor RN: All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation. Endocrinology. 147:1264–1270. 2006. View Article : Google Scholar : PubMed/NCBI
13	Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ and Moore MA: Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood. 104:2893–2902. 2004. View Article : Google Scholar : PubMed/NCBI
14	Vaupel P: The role of hypoxia-induced factors in tumor progression. Oncologist. 9(Suppl 5): 10–17. 2004. View Article : Google Scholar
15	Ohno H, Shirato K, Sakurai T, et al: Effect of exercise on HIF-1 and VEGF signaling. J Phys Fitness Sports Med. 1:5–16. 2012. View Article : Google Scholar
16	Loeffler S, Fayard B, Weis J and Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 115:202–213. 2005. View Article : Google Scholar
17	Xie K, Wei D, Shi Q and Huang S: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15:297–324. 2004. View Article : Google Scholar : PubMed/NCBI
18	Colla S, Tagliaferri S, Morandi F, et al: The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007. View Article : Google Scholar
19	Lee CC, Chen SC, Tsai SC, et al: Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci. 13:143–156. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mizukami Y, Fujiki K, Duerr EM, et al: Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem. 281:13957–13963. 2006. View Article : Google Scholar : PubMed/NCBI
21	Dadiani M, Seger D, Kreizman T, et al: Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer. 16:819–834. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yang Y, Hu Y, Wang Y, Li J, Liu F and Huang L: Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm. Jun 22–2012.(Epub ahead of print).